Tissue PCR sequencing | Tissue allele specific PCR sequencing | Tissue FISH | Tissue IHC | Tissue NGS | ctDNA PCR | ctDNA NGS | Tissue RNA | |
EGFR (sensitizing and T790M) | + | ++ | 0 | 0 | ++ | + | + | + |
HER2 mutation | + | ++ | 0 | 0 | ++ | + | + | + |
METex14 mutation | 0 | ++ | 0 | 0 | ++ | + | + | ++ |
BRAF mutation | + | ++ | 0 | 0 | ++ | + | + | + |
KRAS mutation | + | ++ | 0 | 0 | ++ | + | + | + |
ALK rearrangement | 0 | 0 | ++ | ++ | + | + | + | ++ |
ROS1 rearrangement | 0 | 0 | ++ | 0 | + | 0 | + | ++ |
MET amplification | 0 | 0 | ++ | 0 | + | 0 | + | + |
RET rearrangement | 0 | 0 | ++ | 0 | + | + | + | ++ |
NTRK fusion | 0 | 0 | ++ | + | + | 0 | + | ++ |
NRG1 fusion | 0 | 0 | ++ | + | + | 0 | + | ++ |
HER2 protein expression | 0 | 0 | 0 | ++ | 0 | 0 | 0 | 0 |
PD-L1 protein expression | 0 | 0 | 0 | ++ | 0 | 0 | 0 | 0 |
ALK: anaplastic lymphoma kinase; ctDNA: circulating tumor DNA; EGFR: epidermal growth factor receptor; FISH: fluorescence in situ hybridization; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; NGS: next generation sequencing; NRG1: neuregulin 1; NTRK: neurotrophic receptor tyrosine kinase; PCR: polymerase chain reaction; PD-L1: programmed cell death-ligand 1.
* FISH is highly sensitive but not recommended due to low yield and no approved targeted therapy.